insights_auto
Outlook: 20.0% bullish·30.0% bearish
Go to analysischevron_right
M1RN34:BVMF
Moderna Inc Bdr
R$56.00
0.00%
(0.00) 1D
Oct 9, 5:06:00 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for M1RN34...
Open
R$49.70
High
R$56.00
Low
R$49.30
Mkt. cap
89.83B
Avg. vol.
105.76K
Volume
237.49K
52-wk high
R$56.00
52-wk low
R$6.02
Shares outstanding
399.24M
No. of employees
5K
Open
R$49.70
High
R$56.00
Low
R$49.30
Mkt. cap
89.83B
Avg. vol.
105.76K
Volume
237.49K
52-wk high
R$56.00
52-wk low
R$6.02
Shares outstanding
399.24M
No. of employees
5K
News stories
From web sources and news partners
The Globe and Mail
·
4 hours ago
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
BeInCrypto
·
4 hours ago
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
MarketBeat
·
18 hours ago
11,652 Shares of Moderna, Inc. $MRNA Acquired by Gallagher Capital Advisors LLC
Yahoo Finance
·
1 day ago
Moderna stock hits 4-year high on planned national cancer vaccine effort
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
About Moderna Inc Bdr
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.02B | 678.00M | 389.00M | 145.00M |
Cost of goods sold | 1.01B | 1.23B | 726.00M | 738.00M |
Cost of revenue | 1.01B | 1.23B | 726.00M | 738.00M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 268.00M | 308.00M | 173.00M | 216.00M |
Operating expense | 268.00M | 308.00M | 173.00M | 216.00M |
Total operating expenses | 1.28B | 1.54B | 899.00M | 954.00M |
Operating income | -260.00M | -857.00M | -510.00M | -809.00M |
Other non operating income | -4.00M | -2.00M | - | -2.00M |
EBT including unusual items | -187.00M | -799.00M | -1.33B | -767.00M |
EBT excluding unusual items | -191.00M | -797.00M | -455.00M | -761.00M |
Income tax expense | 13.00M | 27.00M | 9.00M | 15.00M |
Effective tax rate | -6.95% | -3.38% | -0.67% | -1.96% |
Other operating expenses | - | - | - | - |
Net income | -200.00M | -826.00M | -1.34B | -782.00M |
Net profit margin | -19.68% | -121.83% | -345.24% | -539.31% |
Earnings per share | -0.51 | -2.11 | -3.40 | -1.97 |
Interest and investment income | 73.00M | 70.00M | 72.00M | 67.00M |
Interest expense | - | -8.00M | -17.00M | -17.00M |
Net interest expenses | 73.00M | 62.00M | 55.00M | 50.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -208.00M | -790.00M | -451.00M | -746.00M |
Gain or loss from assets sale | - | - | - | - |